Biotest (ETR:BIO) Rating Increased
In a note issued on Friday, 12 February, Kepler Cheuvreux has upped Biotest (ETR:BIO) stock to “Buy” and has set one year target price per share at EUR 17.20. Kepler Cheuvreux’s target is 49.96 % from BIO’s last price.
In spite of the stock rating upgrade ETR:BIO is currently trading -0.14% lower at EUR 13.79 as of 16:34 Frankfurt time. Biotest shares have declined -43.09% in the past 200 days, while the Standard & Poor’s 500 index has decreased -11.49% during the same time.
ETR:BIO Price Chart & Trend
The stock price of Biotest declined 43.09% over the last 200 days, and is in strong down trend. In the last 50 and 100 days, Biotest is down 15.53% and down 26.39%, respectively. Our stocks momentum model is shown on the price chart below.
Source: RightEdge Systems, Yahoo Split & Dividend Adjusted Data and OctaFinance Trading Models
Biotest (ETR:BIO) Profile
Biotest AG is a Germany-based international supplier of biological medications. It diversifies its activities into three business segments: Therapy segment, Plasma and Services segment, as well as Other segment. Its Therapy segment comprises the development and production of blood plasma-based immunoglobulin clotting factors and albumins, which are used in diseases of the immune system, hematological diseases, and intensive care medicine.
Biotest (ETR:BIO) traded down -0.14% on 12 February, hitting EUR 13.79. A total of 11,416 shares of the company’s stock traded hands. This is up from average of 10,494 shares. Biotest has a 52 week low of EUR 12.00 and a 52 week high of EUR 35.3. The company has a market cap of 493.58M EUR and a P/E ratio of 0.
Get the latest Biotest (ETR:BIO) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post Biotest (ETR:BIO) Rating Upgraded to “Buy” at Kepler Cheuvreux with EUR 17.20 Target appeared first on Octafinance.